Principal Financial Group
RXRX icon

Principal Financial Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Principal Financial Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.1K Sell
13,367
-19,794
-60% -$65.9K ﹤0.01% 2133
2026
Q1 		$102K Buy
33,161
+10,959
+49% +$42.3K ﹤0.01% 2125
2025
Q4 		$90.8K Sell
22,202
-5,870
-21% -$29.1K ﹤0.01% 2153
2025
Q3 		$137K Buy
28,072
+3,922
+16% +$20.6K ﹤0.01% 2185
2025
Q2 		$122K Buy
24,150
+4,081
+20% +$20K ﹤0.01% 2160
2025
Q1 		$106K Sell
20,069
-1,280
-6% -$9.33K ﹤0.01% 2093
2024
Q4 		$144K Sell
21,349
-811
-4% -$5.45K ﹤0.01% 2129
2024
Q3 		$146K Sell
22,160
-13,279
-37% -$95.2K ﹤0.01% 2128
2024
Q2 		$266K Sell
35,439
-362,215
-91% -$3.16M ﹤0.01% 2081
2024
Q1 		$3.96M Sell
397,654
-285,954
-42% -$3.18M ﹤0.01% 1640
2023
Q4 		$6.74M Buy
683,608
+38,133
+6% +$272K ﹤0.01% 1457
2023
Q3 		$4.94M Buy
645,475
+604,618
+1,480% +$6.03M ﹤0.01% 1541
2023
Q2 		$305K Buy
40,857
+1,912
+5% +$13.4K ﹤0.01% 2076
2023
Q1 		$260K Buy
38,945
+4,462
+13% +$35.4K ﹤0.01% 2121
2022
Q4 		$266K Buy
34,483
+1,603
+5% +$15.7K ﹤0.01% 2137
2022
Q3 		$350K Buy
32,880
+6,701
+26% +$67.9K ﹤0.01% 2038
2022
Q2 		$213K Sell
26,179
-9,019
-26% -$60.3K ﹤0.01% 2285
2022
Q1 		$252K Sell
35,198
-273
-0.8% -$2.9K ﹤0.01% 2284
2021
Q4 		$608K Buy
+35,471
New +$667K ﹤0.01% 2082

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Principal Financial Group's RXRX Position: Q2 2026 in Review

Principal Financial Group reduced its Recursion Pharmaceuticals (RXRX) stake by 60% in Q2 2026, selling an estimated $65.9K and leaving 13,367 shares worth $49.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2133.

Principal Financial Group first reported a position in RXRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $6.74M in Q4 2023. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Principal Financial Group held 13,367 shares of Recursion Pharmaceuticals worth $49.1K as of Q2 2026.
  • Principal Financial Group sold 19,794 Recursion Pharmaceuticals shares in Q2 2026, an estimated $65.9K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #2133 holding.
  • Principal Financial Group first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • Principal Financial Group's Recursion Pharmaceuticals position peaked at $6.74M in Q4 2023.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.